WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳
← All Claim Checks
Source record · FDA evidence review and human biomarker study · reviewed July 18, 2026

The human record does not establish telomere-based age reversal or longer life.

Misleading
The circulating claim

“Epitalon lengthens telomeres and reverses aging in people.”

What the source record says

FDA identified one small human biomarker study relevant to circadian-gene expression, not a clinical trial showing age reversal, longer life, or improved patient outcomes. FDA also says it found no clinical human safety studies for Epitalon-related substances.

Why the claim misleads

Biomarker and laboratory findings are being converted into a demonstrated whole-person anti-aging outcome.

Correction

The human record does not establish telomere-based age reversal or longer life.

Primary sources
FDA Epitalon briefing document, 2026Open source ↗Ivko et al. — AEDG and circadian-gene expressionOpen source ↗Epitalon library entryOpen source ↗
What changed

Added the source-verified Claim Check to the structured claim/source/change registry.

What would change our answer

A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.

Version history · 1 entry
  1. v1 · 2026-07-18Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.